Changes in the cost‐effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults
Authors:
- Angela R. WateskaAWAngela R. Wateska
- Mary Patricia NowalkMNMary Patricia Nowalk
- Shoroq M. AltawalbehSAShoroq M. Altawalbeh
- Chyongchiou J. LinCLChyongchiou J. Lin
- Lee H. HarrisonLHLee H. Harrison
- William SchaffnerWSWilliam Schaffner
- Richard K. ZimmermanRZRichard K. Zimmerman
- Kenneth J. SmithKSKenneth J. Smith
Open Access
- 1 June 2024
- journal article
- research article
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 72 (8) , 2423-2433
Abstract
Background: Multiple factors, such as less complex U.S. adult pneumococcal recommendations that could increase vaccination rates, childhood pneumococcal vaccination indirect effects that decrease adult vaccination impact, and increased vaccine hesitancy (particularly in underserved minorities), could diminish the cost‐effectiveness of programs to increase pneumococcal vaccination in older adults. Prior analyses supported the economic favorability of these programs. Methods: A Markov model compared no vaccination and current recommendations (either 20‐valent pneumococcal conjugate vaccine [PCV20] alone or 15‐valent pneumococcal conjugate vaccine plus the 23‐valent pneumococcal polysaccharide vaccine [PCV15/PPSV23]) without or with programs to increase vaccine uptake in Black and non‐Black 65‐year‐old cohorts. Pre‐pandemic population‐ and serotype‐specific pneumococcal disease risk and illness/vaccine costs came from U.S. databases. Program costs were $2.19 per vaccine‐eligible person and increased absolute vaccination likelihood by 7.5%. Delphi panel estimates and trial data informed vaccine effectiveness values. Analyses took a healthcare perspective, discounting at 3%/year over a lifetime time horizon. Results: Uptake programs decreased pneumococcal disease overall. In Black cohorts, PCV20 without program cost $216,805 per quality‐adjusted life year (QALY) gained compared with no vaccination; incremental cost‐effectiveness was $245,546/QALY for PCV20 with program and $425,264/QALY for PCV15/PPSV23 with program. In non‐Black cohorts, all strategies cost >$200,000/QALY gained. When considering the potential indirect effects from childhood vaccination, all strategies became less economically attractive. Increased vaccination with less complex strategies had negligible effects. In probabilistic sensitivity analyses, current recommendations with or without programs were unlikely to be favored at thresholds <$200,000/QALY gained. Conclusion: Current U.S. pneumococcal vaccination recommendations for older adults were unlikely to be economically reasonable with or without programs to increase vaccine uptake. Alternatives to current pneumococcal vaccines that include pneumococcal serotypes associated with adult disease should be considered.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01 AI11657503)
This publication has 22 references indexed in Scilit:
- Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adultsVaccine, 2023
- Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysisVaccine, 2021
- Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. SeniorsAmerican Journal of Preventive Medicine, 2021
- Social media and vaccine hesitancy: new updates for the era of COVID-19 and globalized infectious diseasesHuman Vaccines & Immunotherapeutics, 2020
- Pneumococcal vaccination in older adults: An initial analysis of social determinants of health and vaccine uptakeVaccine, 2020
- Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 YearsJournal of Community Health, 2019
- Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.Open Forum Infectious Diseases, 2017
- Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United StatesJournal of General Internal Medicine, 2016
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY ThresholdNew England Journal of Medicine, 2014
- Safety of Revaccination With Pneumococcal Polysaccharide VaccineJAMA, 1999